Foshan Maagenta Biotechnology Co. Ltd – Trademark Portfolio

Entity Type: 99

Foshan Maagenta Biotechnology Co. Ltd holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include NESPELAC. The owner is based in Foshan, Guangdong.

Zone 3rd Rd, Fengchong, Lishui

2F/3F Building #1, No.8 Xiaxi Industrial

Foshan, Guangdong 528241 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

NESPELAC
NESPELAC
Registered 2024

Trademark Classifications

Foshan Maagenta Biotechnology Co. Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Foshan Maagenta Biotechnology Co. Ltd have?

Foshan Maagenta Biotechnology Co. Ltd has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Foshan Maagenta Biotechnology Co. Ltd file in?

Foshan Maagenta Biotechnology Co. Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 3 (Cosmetics & Cleaning). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.

What are Foshan Maagenta Biotechnology Co. Ltd's most well-known trademarks?

Foshan Maagenta Biotechnology Co. Ltd's registered trademark portfolio includes well-known marks such as NESPELAC. These are among 1 currently registered trademark in the portfolio.

What is Foshan Maagenta Biotechnology Co. Ltd's trademark registration success rate?

Foshan Maagenta Biotechnology Co. Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.